DEVELOPMENT OF A DENGUE VACCINE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 目的：研制登革热病毒疫苗。 登革热病毒威胁着世界三分之一以上的人口，每年估计造成1亿至1.5亿登革热病例。Inviragen的登革热疫苗是由疾病控制和预防中心(CDC)的合作者设计的，以预防所有四种登革热病毒。在临床前动物模型中，该疫苗已被证明是安全有效的。 我们已经建立了非人类灵长类动物模型来测试一种用于人类临床开发的实验性登革热疫苗。我们正在探索一种嵌合四价疫苗的临床前开发。 这项研究使用了动物服务和研究服务。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objective: To develop a vaccine for dengue viruses. Dengue viruses threaten over a third of the world's population and cause an estimated 100 - 150 million cases of dengue fever every year. InViragen's dengue vaccine was designed by collaborators at the Centers for Disease Control and Prevention (CDC) to protect against all four of the dengue viruses. The vaccine has been shown to be safe and effective in preclinical animal models. We have set up nonhuman primate animal models to test an experimental dengue vaccine for human clinical development. We are exploring preclinical development of a chimeric tetravalent vaccine. This research uses Animal Services and Research Services.